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ABSTRACT 
Over the last decades, the use of photodynamic therapy (PDT) for the treatment of various types 
of cancer as well fungal, viral and bacterial infections has received increasing attention. Despite 
its clinical success, the currently approved photosensitizers (PSs) are associated with poor water 
solubility, aggregation, low photostability and a long excretion time. To overcome these 
limitations, much research is devoted towards the development of PSs based on transition metal 
complexes. However, the majority of metals used for this purpose are rare and expensive. 
Therefore, it would be of high interest to develop effective PDT PSs based on cheap and 
abundant metals. In this article, the use of Cu(II) and Ni(II) dipyrrin complexes as potential 
PDT PSs against cancer is presented. As required for PDT applications, these complexes were 
found to have a strong absorption in the green spectrum and to be stable in an aqueous solution 
in the dark as well as upon light irradiation. Biological studies revealed that the complexes have 
a very low cytotoxic effect in the dark with a slight effect upon irradiation at 510 nm in human 
cervical carcinoma (HeLa) cells. 
 
Highlights: 
- Synthesis and characterisation of two Cu(II) and Ni(II) dipyrrin complexes. 
- Investigations of the use of these compounds as chemotherapeutic and photodynamic 
therapy agents. 
- Photophysical studies studied revealed absorption in the biological spectral window. 
- (Photo-)cytotoxicity of the metal complexes in cancerous human cervical carcinoma 
cells was assessed. 
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1.  Introduction 
Dipyrrins are small organic molecules consisting of two pyrroles moieties, which are linked 
together over a methionine group. Upon deprotonation, the ligand scaffold benefits from 
resonance stabilisation, which enables it to act as a bidentate ligand and to coordinate to metal 
ions. As the predominant class of compounds, 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 
(BODIPY) complexes and its derivatives are highly investigated due to their attractive 
photophysical properties, which include high stability in a biological environment and sharp 
fluorescence with very high quantum yields. These photophysical properties initiated extensive 
research for the use of these compounds as biomedical fluorescence probes or chemical 
sensors.1-4 Apart from boron, the dipyrrin ligand scaffold is also able to coordinate to many 
other metal ions like, for example, Ni(II),  Zn(II),  Cd(II), Cu(II),  Fe(III), Ga(III), Co(III), In(III) 
and  Rh(III). Due to the possibility to generate nanoarchitectures, these compounds have found 
application as one-dimensional nanowires, two-dimensional nanosheets or metal-organic 
frameworks (MOFs).5-14 Recently, research has shifted to employ the great photophysical 
properties of bis(dipyrrinato)metal(II) and tris(dipyrrinato)metal(III) complexes in other fields 
of research.15-18 Exemplary, the use of bis(dipyrrinato)Zn(II) complexes as fluorescent probes 
has gained much interest. Despite much progress in the tuning of the photophysical properties 
of these complexes, the corresponding BODIPY complexes remain the best of the class.19-24  
Next to applications as fluorescent probes, dipyrrin complexes and especially BODIPY 
complexes have also recently received attention for their utilisation as photosensitizers (PSs) 
for photodynamic therapy (PDT) for the treatment of bacterial, fungal or viral infections as well 
as various types of cancer (e.g., lung, bladder, oesophageal, and brain cancer).25-30 During a 
PDT treatment, a PS is injected, either locally or systemically. After a certain circulation time 
to allow for accumulation of the PS in the targeted region, the target is exposed to light at a 
specific wavelength, enabling activation of the PS. The latter then generates photocatalytically 
reactive oxygen species (ROS). Although different kinds of radials can be involved in this 
process, the majority of PSs are generating singlet oxygen (1O2). As ROS and 1O2 are highly 
reactive, oxidative stress is caused and cell death triggered.31-35  
To date, the majority of PSs are based on a tetrapyrrolic scaffold (i.e., porphyrin, chlorine). 
Despite their undeniable clinical success, the status of these PDT agents generally remains 
unsatisfactory. These compounds are generally associated with poor water solubility, 
aggregation, low photostability and a long excretion time of the body, leading to 
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photosensitivity.36, 37  To overcome these limitations, much research is devoted towards the 
development of new classes of PDT PSs or the improvement of the currently approved PDT 
PSs. Among other concepts, the introduction of a metal ion into a PDT PS was found to 
sometimes overcome these drawbacks. For example, the tetrapyrrolic compounds complexed 
with Sn(IV) (Purlytin®), Lu(III) (Lutrin®/Antrin®), Al(III) (Photosens®) and Pd(II) 
(TOOKAD®/TOOKAD soluble®) have been or are currently investigated in clinical trials or 
have even been approved.38, 39 In addition, the Ru(II) polypyridyl complex TLD-1433 is 
currently investigated in Phase II clinical trials to treat certain types of bladder cancer. 
Therefore, much efforts are devoted towards the development of transition metal complexes as 
PDT PSs.40 The majority of complexes studied are based on Ru(II),41-51 Os(II),52-54 Ir(III),55-61 
Rh(III)62-64 and Re(I).65-69 As these metals are expensive, it would be of high interest to develop 
PSs based on cheap, abundant metals. With this aim in mind, we have recently investigated the 
use of Fe(II) polypyridine complexes as potential PDT PSs.70, 71 
Based on the clinical success of tetrapyrrolic compounds and the high potential of transition 
metal complexes, it would be of great interest to combine both concepts by preparing 
bis(dipyrrinato)metal(II) complexes based on cheap, abundant metals. In this context, we have 
recently described bis(dipyrrinato)Zn(II) complexes with exceptionally long excited state 
lifetimes. By placing iodine atoms on the ligand scaffold, the heavy atom effect was able to 
promote the intersystem crossing process, generating PDT active compounds.72 Capitalising on 
these results, we were interested in determining if the scope of metals used for this purpose 
could be extended. In this article, we report our results on the use of Cu(II) and Ni(II) dipyrrin 
complexes. This class of complexes has been previously studied in the literature primarily due 
to their electrochemical properties, their ability to form nanoarchitectures but also their catalytic 
properties like the generation of hydroxyl radials.73-79 Although the majority of Ni(II) and Cu(II) 
complexes are known to be non-luminescent, some compounds including the structurally 
related Cu(II)(5-phenyldipyrromethene)2 and Cu(II)(1,5,9-triphenyldipyrromethene)2 
complexes were previously found to be emitting.80-82 Capitalising on these studies, two new 
compounds (complexes 1-2) were synthesised and characterised in depth, including by single 
crystal X-ray diffraction. Their potential as PDT PSs is reported. 
 
2. Experimental Section 
2.1. Instrumentation and methods 
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1H and 13C NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer. Chemical 
shifts (δ) are reported in parts per million (ppm) referenced to tetramethylsilane (δ 0.00) ppm 
using the residual proton solvent peaks as internal standards. Coupling constants (J) are reported 
in Hertz (Hz) and the multiplicity is abbreviated as follows: s (singlet). ESI-MS experiments 
were carried out using a LTQ-Orbitrap XL from Thermo Scientific (Thermo Fisher Scientific) 
and operated in positive ionization mode. Elemental microanalyses were performed on a 
Thermo Flash 2000 elemental analyzer.  
 
2.2. Materials 
All chemicals were obtained from commercial sources and were used without further 
purification. Dulbecco’s Modified Eagles Medium (DMEM), Dulbecco’s Modified Eagles 
Medium supplemented with nutrient mixture F-12 (DMEM/F-12), Fetal Bovine Serum (FBS), 
Gibco Penicillin-Streptomycin-Glutamine (Penstrep), Dulbecco’s Phosphate-Buffered Saline 
(PBS) were purchased from Fisher Scientific and Resazurin from ACROS Organics. 
 
2.3. Synthesis 
(Z)-2-((3,5-dimethyl-2H-pyrrol-2-ylidene)(mesityl)methyl)-3,5-dimethyl-1H-pyrrole: 
2,4,6-Trimethylbenzaldehyde  (200 mg, 1.35 mmol) and 2,4-dimethylpyrrole (322 mg, 3.38 
mmol) were dissolved in dry dichloromethane (30 mL) under N2 atmosphere. Trifluoroacetic 
acid (100 L) was added and the reaction mixture was stirred at room temperature for 24 h. 
After this time, tetrachloro-p-benzoquinone (332 mg, 1.35 mmol) was added and the reaction 
mixture stirred additional 4 h. Afterwards the solution was filtered and the solvent evaporated. 
The crude product was purified by column chromatography on neutral alumina with a gradient 
of dichloromethane/hexane. The fractions containing the product were united and the solvent 
was removed. The solid was washed with Et2O and dried. The compound was used for the next 
synthetic step without further purification. 
(Z)-3-iodo-5-((4-iodo-3,5-dimethyl-2H-pyrrol-2-ylidene)(mesityl)methyl)-2,4-dimethyl-
1H-pyrrole: 
(Z)-2-((3,5-dimethyl-2H-pyrrol-2-ylidene)(mesityl)methyl)-3,5-dimethyl-1H-pyrrole (318 mg, 
1 mmol) was dissolved in a 1:1 chloroform/ethanol (150 mL) mixture to which iodine (508 mg, 
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2 mmol) and iodic acid (352 mg, 2 mmol) was added portion wise. The mixture was stirred at 
room temperature for 4 h under N2 atmosphere. After this time, the mixture was diluted with 
chloroform (500 mL) and the organic layer was washed three-times with 5% sodium sulphite 
solution (200 mL). The product was dried over anhydrous sodium sulphate and the solvent was 
evaporated. The compound was used for the next synthetic step without further purification. 
Bis((Z)-3-iodo-5-((4-iodo-3,5-dimethyl-2H-pyrrol-2-ylidene)(mesityl)methyl)-2,4-
dimethyl-1H-pyrrole)nickel(II) (1): 
(Z)-3-iodo-5-((4-iodo-3,5-dimethyl-2H-pyrrol-2-ylidene)(mesityl)methyl)-2,4-dimethyl-1H-
pyrrole (200 mg, 0.35 mmol) was dissolved in a mixture of 3:2:3 butanol/ethanol/H2O (250 
mL). Ni(OAc)2 . 4H2O (35 mg, 0.14 mmol) and Et3N (142 mg, 1.4 mmol) were added and the 
reaction mixture heated at reflux for 24 h under nitrogen atmosphere. After completion of the 
reaction, the solvent was removed. The crude product was purified by column chromatography 
on silica with a gradient of dichloromethane/pentane. The fractions containing the product were 
united and the solvent was removed. The solid was washed with Et2O and dried. Yield: 53%. 
1H-NMR (CD2Cl2, 400 MHz): 6.98 (s, 4H), 2.35 (s, 6H), 2.09 (s, 12H), 2.05 (s, 12H), 1.53 (s, 
12H). 13C-NMR (CD2Cl2, 100 MHz): 157.8, 145.6, 144.4, 139.3, 136.2, 135.1, 129.2, 129.0, 
84.3, 23.2, 19.6, 17.8, 17.5. ESI-HRMS (pos. detection mode): calcd for C44H47I4N4Ni [M+H]+ 
m/z 1196.9333; found: 1196.9327, UV/VIS (CH2Cl2) λmax (ε x 103): 526 (117.7), 392 (17.5) 
nm, Elemental analysis calcd for C44H46I4N4Ni (%): C 44.14, H 3.87, N 4.69; found: C 44.36, 
H 3.95, N 4.31. 
Bis((Z)-3-iodo-5-((4-iodo-3,5-dimethyl-2H-pyrrol-2-ylidene)(mesityl)methyl)-2,4-
dimethyl-1H-pyrrole)copper(II) (2): 
(Z)-3-iodo-5-((4-iodo-3,5-dimethyl-2H-pyrrol-2-ylidene)(mesityl)methyl)-2,4-dimethyl-1H-
pyrrole (200 mg, 0.35 mmol) was dissolved in a mixture of 3:2:3 butanol/ethanol/H2O (250 
mL). Cu(OAc)2 (25 mg, 0.14 mmol) and Et3N (142 mg, 1.4 mmol) were added and the reaction 
mixture heated at reflux for 24 h under nitrogen atmosphere. After completion of the reaction, 
the solvent was removed. The crude product was purified by column chromatography on silica 
with a gradient of dichloromethane/pentane. The fractions containing the product were united 
and the solvent was removed. The solid was washed with Et2O and dried. Yield: 74%. ESI-
HRMS (pos. detection mode): calcd for C44H47I4N4Cu [M+H]+ m/z 1201.9275; found: 
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1201.9278, UV/VIS (CH2Cl2) λmax (ε x 103): 526 (96.2), 392 (14.0) nm, Elemental analysis 
calcd for C44H46I4N4Cu (%): C 43.97, H 3.86, N 4.66; found: C 43.72, H 4.09, N 4.49. 
 
2.4. X-ray crystallography 
Single crystal X-ray diffraction data were collected at 183(1) K on a Rigaku OD Synergy 
(Pilatus 200K detector) diffractometer for 1 and on a Rigaku OD Supernova (Atlas CCD 
detector) diffractometer for 2 equipped with Oxford liquid-nitrogen Cryostream coolers and 
using a single wavelength X-ray source from a micro-focus sealed X-ray tube with the Cu Kα 
radiation (λ = 1.54184 Å). The selected single crystals were mounted using polybutene oil on a 
flexible loop fixed on a goniometer head and transferred to the diffractometer. Pre-experiments, 
data collections, data reductions and analytical absorption corrections83 were performed with 
the program suite CrysAlisPro.84 Using Olex2,85 the structures were solved with the SHELXT86 
small molecule structure solution program and refined with the SHELXL2018/3 program 
package87 by full-matrix least-squares minimization on F2. The crystal data collections and 
structure refinement parameters are summarized in Table 1. CCDC 1976222 (for 1) and 
1976221 (for 2) contain the supplementary crystallographic data for these compounds, and can 
be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
In the crystal structure of 1, the Ni complex lies on a two-fold axis, only half of the molecule 
had to be refined the second half being reproduced by a symmetry operation. Solvent molecules 
of methanol cocrystallized with the main species but a reasonable modelling of the disordered 
positions could not be obtained. The PLATON SQUEEZE tool88 was used to calculate the 
number of electrons attributed to solvent molecules in the primitive cell and to take this solvent 
contribution into account in the calculated structure factors. A ratio of three molecules of 
methanol for one molecule of the Ni complex was considered. In the crystal structure of 2, two 
crystallographically independent molecules of the Cu complex are present in the asymmetric 
unit. Solvent molecules of hexane cocrystallized with the main species but like for 1 a 
reasonable modelling of the disordered positions could not be obtained. The PLATON 
SQUEEZE tool was and a ratio of four molecules of the Cu complex for one molecule of solvent 
was considered. For both structures the solvent molecules were included in the CIF files 
(formula sum and formula moiety) causing many alerts in the IUCr checkCIF reports. 
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2.5. Spectroscopic measurements 
The absorption and emission of the samples has been measured with a SpectraMax M2 
Spectrometer (Molecular Devices). For the determination of the luminescence quantum yield, 
the samples were prepared in degassed CH2Cl2 solution with an absorbance of 0.1 at 520 nm. 
The luminescence quantum yields were calculated by comparison with the reference 
Rhodamine B in ethanol (Φem=0.50)89 applying the following formula: 
Φୣ୫,ୱୟ୫୮୪ୣ ൌ  Φୣ୫,୰ୣ୤ୣ୰ୣ୬ୡୣ ∗  𝐹୰ୣ୤ୣ୰ୣ୬ୡୣFୱୟ୫୮୪ୣ ∗
Iୱୟ୫୮୪ୣ
I୰ୣ୤ୣ୰ୣ୬ୡୣ  ∗ ൬
nୱୟ୫୮୪ୣ
n୰ୣ୤ୣ୰ୣ୬ୡୣ൰
ଶ
 
F ൌ  1 െ 10ି஺ 
Φem = luminescence quantum yield, F = fraction of light absorbed, I = integrated emission 
intensities, n = refractive index, A = absorbance of the sample at irradiation wavelength 
 
2.6. Singlet oxygen measurements  
- direct evaluation 
The samples were prepared in an air saturated CH3CN or D2O solution with an absorbance of 
0.2 at 450 nm. This solution was irradiated in fluorescence quartz cuvettes (width 1 cm) using 
a mounted M450LP1 LED (Thorlabs) whose irradiation, centred at 450 nm, has been focused 
with aspheric condenser lenses. The intensity of the irradiation has been varied using a T-Cube 
LED Driver (Thorlabs) and measured with an optical power and energy meter. The emission 
signal was focused and collected at right angle to the excitation pathway and directed to a 
Princeton Instruments Acton SP-2300i monochromator. A longpass glass filter was placed in 
front of the monochromator entrance slit to cut off light at wavelengths shorter than 850 nm. 
The slits for detection were fully open. As a detector an EO-817L IR-sensitive liquid nitrogen 
cooled germanium diode detector (North Coast Scientific Corp.) has been used. The singlet 
oxygen phosphorescence at 1270 nm was measured by recording spectra from 1100 to 1400 nm. 
For the data analysis, the singlet oxygen luminescence peaks at different irradiation intensities 
were integrated. The resulting areas were plotted against the percentage of the irradiation 
intensity and the slope of the linear regression calculated. The absorbance of the sample was 
corrected with an absorbance correction factor. As reference for the measurement in a D2O 
solution [Ru(bipy)3]Cl2 (ΦRu(bipy)₃Cl₂ = 0.22)90 was used and the singlet oxygen quantum yields 
were calculated using the following formula: 
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𝛷ୱୟ୫୮୪ୣ ൌ 𝛷୰ୣ୤ୣ୰ୣ୬ୡୣ ൈ Sୱୟ୫୮୪ୣS୰ୣ୤ୣ୰ୣ୬ୡୣ ൈ
I୰ୣ୤ୣ୰ୣ୬ୡୣ
Iୱୟ୫୮୪ୣ  
I ൌ I଴ ൈ ሺ1 െ 10ି஺ሻ 
 
Φ = singlet oxygen quantum yield, S = slope of the linear regression of the plot of the areas of 
the singlet oxygen luminescence peaks against the irradiation intensity, I = absorbance 
correction factor, I0 = light intensity of the irradiation source, A = absorbance of the sample at 
irradiation wavelength. 
 
- indirect evaluation 
For the measurement in CH3CN: The samples were prepared in an air-saturated CH3CN 
solution containing the complex with an absorbance of 0.1 at the irradiation wavelength, N,N-
dimethyl-4-nitrosoaniline aniline (RNO, 24 µM) and imidazole (12 mM). For the measurement 
in PBS buffer: The samples were prepared in an air-saturated PBS solution containing the 
complex with an absorbance of 0.1 at the irradiation wavelength, N,N-dimethyl-4-nitrosoaniline 
aniline (RNO, 20 µM) and histidine (10 mM). The samples were irradiated on 96 well plates 
with an Atlas Photonics LUMOS BIO irradiator for different times. The absorbance of the 
samples was measured during these time intervals with a SpectraMax M2 Microplate Reader 
(Molecular Devices). The difference in absorbance (A₀-A) at 420 nm for the CH3CN solution 
or at 440 nm a PBS buffer solution was calculated and plotted against the irradiation times. 
From the plot the slope of the linear regression was calculated as well as the absorbance 
correction factor determined. The singlet oxygen quantum yields were calculated using the 
same formulas as used for the direct evaluation.  
 
2.7. Stability in CH2Cl2/H2O 
The stability of the complex in CH2Cl2 or H2O (2% DMSO, v%) was investigated by UV/Vis 
spectroscopy. The complex was dissolved with about 0.5 absorption at its absorption maximum 
and stored at room temperature in the dark. The absorption spectrum from 300-600 nm was 
recorded with a SpectraMax M2 Microplate Reader (Molecular Devices) after each time 
interval (0, 1, 4, 12, 24, 48 h) and compared. 
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2.8. Photostability  
The photostability of the complex in CH2Cl2 was investigated by UV/Vis spectroscopy. The 
complex was dissolved with about 0.5 absorption at its absorption maximum and exposed to a 
constant LED irradiation 510 nm (4.2 mW/cm2) with an Atlas Photonics LUMOS BIO 
irradiator. The absorption spectrum from 300-600 nm was recorded with a SpectraMax M2 
Microplate Reader (Molecular Devices) after each time interval (0, 5, 10, 20, 30 min) and 
compared. 
 
2.9. (Photo-)cytotoxicity  
The cytotoxicity of the complexes was assessed by measuring cell viability using a fluorometric 
resazurin assay. The cultivated cells were seeded in triplicates in 96 well plates with a density 
of 4000 cells per well in 100 μL of media. After 24 h, the medium was removed and the cells 
were treated with increasing concentrations of the complex diluted in cell media achieving a 
total volume of 200 μL. The cells were incubated with the complex for 4 h. After this time, the 
media was removed and replaced with 200 μL of fresh medium. For the phototoxicity studies, 
the cells were exposed to light with an Atlas Photonics LUMOS BIO irradiator. Each well was 
constantly illuminated with either a 510 nm irradiation. During this time, the temperature was 
maintained constantly at 37 °C. The cells were grown in the incubator for additional 44 h. For 
the determination of the dark cytotoxicity, the cells were not irradiated and after the medium 
exchange directly incubated for 44 h. After this time, the medium was replaced with fresh 
medium containing resazurin with a final concentration of 0.2 mg/mL. After 4 h incubation, the 
amount of the fluorescent product resorufin was determined upon excitation at 540 nm and 
measurement its emission at 590 nm using a SpectraMax M2 Microplate Reader (Molecular 
Devices). The obtained data was analyzed with the GraphPad Prism software. 
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3. Results and Discussion  
3.1. Synthesis 
The Ni(II) (1) and Cu(II) (2) complexes were synthesised as visualised in Scheme 1. In the first 
step, the ligand scaffold was generated by reacting 2,4,6-trimethylbenzaldehyde with 2, 4-
dimethylmethylpyrrole using catalytic amounts of trifluoracetic acid. The ligand was then 
oxidised using tetrachloro-p-benzoquinone, achieving a complete conjugation of the aromatic 
system. Following this, the peripheral positions were iodinated using a mixture of iodine and 
iodic acid. At last, the metal ion was coordinated using the corresponding acetate salt. While 
the Cu(II) complex (2) is paramagnetic, the analogous Ni(II) complex (1) was found to be 
diamagnetic and was therefore characterised by 1H- and 13C-NMR (Figures S1-S2). Worthy of 
note, structurally related Ni(II) complexes were also found to be diamagnetic.73-75,77 
 
Scheme 1. Synthetic procedures for the synthesis of 1-2. a) TFA, CH2Cl2; b) Tetrachloro-p-
benzoquinone; c) CHCl3:EtOH (1:1), I2, HIO3; d) butanol/ethanol/H2O (3:2:3), Et3N, 1: 
Cu(OAc)2, 2: Ni(OAc)2 . 4H2O. 
 
3.2. X-ray crystallography 
The nickel and copper centers in 1 and 2 (Figure 1, Table S1) adopt a distorted tetrahedral 
geometry coordinated by the four nitrogen atoms of the two substituted dipyrrinato ligands. The 
Ni–N bond lengths are 1.930(7) and 1.937(5) Å while the Cu–N bond lengths fall in the similar 
range 1.931(3) – 1.950(3) Å (from two crystallographically independent molecules). The N–
M–N bond angles are 92.8(2)° in 1 (Ni) and 92.89(13) – 93.67(13)° in 2 (Cu), and the dihedral 
angles between the two N-M-N planes are 80.99° in 1 (Ni) and 65.11 – 69.00° in 2 (Cu). In the 
Cambridge Structural Database,91 reported α,α′-substituted analogues show dihedral angles in 
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the range of 83.6 – 86.2° for Ni complexes77, 92, 93 and 62.9 – 66.9° for Cu complexes.77, 81, 92, 93 
Consequently, the geometry of our two new molecules seems to be typical for such metal 
complexes. Although Ni(II) and Cu(II) complexes favor square planar coordinations, steric 
repulsion between the methyl groups at the α position of the dipyrrinato ligand prevent planar 
structures in these complexes. The same feature is observed in our previously reported 
bis(dipyrrinato)zinc(II) complex.72  
 
 
Figure 1. a) Molecular structure of 1 (all H atoms are omitted for clarity). The thermal 
ellipsoids are drawn at the 20% probability level. b) Molecular structure of 2 (one of the two 
independent molecules; all H atoms are omitted for clarity). The thermal ellipsoids are drawn 
at the 50% probability level. 
 
 
3.3. Photophysical Properties 
After chemical characterisation of the complexes, their photophysical properties were evaluated 
in view of applications as PDT PSs. An important factor during a PDT treatment is the 
wavelengths employed as this directly correlates with the light penetration depth inside tissue. 
Worthy of note, there is no ideal wavelength for a treatment as this depends, among others, on 
the tumour size and localisation. Very importantly, it has to be ensured that only tumour tissue 
and not underlying healthy tissue is damaged. However, with the aim to treat deep seated or 
large tumors, much research is devoted towards the development of PSs with an absorption in 
or near the biological spectral window (600-900 nm). This would allow light to penetrate 
significantly deeper inside tissue/tumour. Having this in mind, the absorption profile of the 
complexes 1-2 were measured (Figure 2). Both complexes were found to have a strong 
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absorption at 526 nm, which is significantly more red-shifted than many transition metal 
complexes investigated for PDT applications. Interestingly, both complexes showed a highly 
similar absorption profile, indicating that the coordinated metal does not drastically influence 
this property. Worthy of note, previously reported Ni(II) and Cu(II) dipyrrin complexes were 
found to have similar absorption profiles.94-96 Following this, the luminescence of the 
complexes upon irradiation at 520 nm was investigated. While no signal for the Ni(II) complex 
1 was detected, a low emission signal with a luminescence quantum yield of >0.1% and a 
maximum at 551 nm for the Cu(II) complex 2 was detected (Figure S3). This result is in 
agreement with the luminescence study of structurally related Cu(II)(dipyrrin)2 complexes.81 
 
Figure 2. Absorption spectra of 1-2 in CH2Cl2. 
 
Subsequently, the ability of complexes 1 and 2 to generate singlet oxygen (1O2), which is 
considered the predominant toxic species in PDT upon irradiation at 450 and 510 nm was 
investigated by two complementary methods: 1) direct by measurement of the phosphorescence 
of 1O2, 2) indirect by following the change in absorption of a 1O2 scavenger. The experiment 
was performed in the organic solvent CH3CN and in an aqueous solution. The results showed 
that both complexes are poorly generating 1O2 at the detection limit of our used apparatus with 
quantum yields >1% in CH3CN and in an aqueous solution.   
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3.4. Stability  
As a crucial parameter for PDT applications, the stability of a compound needs to be 
investigated as previous studies have shown that this could be problematic.97-99 To do so, 
complexes 1-2 were incubated in the dark for varying time points (0 h, 1 h, 4 h, 12 h, 24 h and 
48 h) in CH2Cl2 and H2O and the corresponding absorption spectra monitored (Figure S4-S7). 
As no significant difference were observed, the stability of both metal complexes is indicated. 
Beside the stability in a chemical environment, the stability upon irradiation remains a different 
issue. Therefore, the complexes were exposed to light at 510 nm and their absorption spectra 
monitored for varying time points (0, 5, 10 20 and 30 min). Only minimal changes were 
observed (Figure S8-S9), suggesting that the complexes are stable upon light irradiation. 
 
3.5. (Photo-)cytotoxicity 
After an analysis of the chemical and photophysical properties of the compounds, their 
cytotoxicity on non-cancerous retinal pigment epithelium (RPE-1) and human cervical 
carcinoma (HeLa) cells in the dark as well as upon irradiation at 510 nm (20 min, 5.0 J/cm2) 
was investigated using a fluorometric resazurin assay. The results (Table 1) show that the 
compounds have a very low cytotoxic effect in the dark. Interestingly, the obtained IC50 values 
of both compounds were found in the same range, indicating that the central metal does not 
significantly influence this property. Unfortunately, light irradiation was found to have only a 
negligible effect on the cell viability. This is most likely caused by the poor photophysical 
properties (i.e., 1O2 generation) of complexes 1-2.  In comparison, the PS Protoporphyrin IX 
(PpIX) and the anticancer drug cisplatin were found to have drastically lower IC50 values. 
 
Table 1. IC50 value (μM) in the dark and upon irradiation at 510 nm (20 min, 5.0 J/cm2) for 
complexes 1-2, the PDT PS Protoporphyrin IX (PpIX) and the anticancer drug cisplatin in non-
cancerous retinal pigment epithelium (RPE-1) and human cervical carcinoma (HeLa) cells. 
Average of three independent measurements. 
 HeLa RPE-1 
 dark 510 nm dark 510 nm 
1 157.1 ± 8.9 159.3 ± 9.1 184.3 ± 6.3 179.5 ± 7.0 
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2 148.3 ± 7.4 133.9 ± 8.5 172.4 ± 8.6 163.1 ± 8.9 
PpIX >100 2.8 ± 0.2 >100 4.1 ± 0.2 
cisplatin 10.5 ± 0.8 - 23.9 ± 1.4 - 
 
4. Conclusions 
In this study, the role of the metal ions Ni(II) and Cu(II) on the photophysical and biological 
properties of homoleptic dipyrrin complexes was investigated. Both metal complexes prepared 
were characterised in-depth, including by single crystal X-ray diffraction. The complexes were 
found to have a strong absorption in the green area of the electromagnetic spectrum, which is a 
desired property for PDT agent. Photophysical studies demonstrated that these complexes were 
poorly emissive and barely produced 1O2 upon irradiation. Stability studies indicated that both 
compounds were stable in a biological environment and upon light irradiation. Biological 
evaluation of the compounds in non-cancerous retinal pigment epithelium and human cervical 
carcinoma cells revealed a very low cytotoxicity in the dark, as requested for a PDT agent. 
However, only a negligible effect on cell viability was observed upon light irradiation. This is 
most likely caused by the poor photophysical properties (i.e. 1O2 generation) of the complexes. 
We are currently pursuing other options to design PDT PSs based on cheap, abundant metals. 
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